The Defense Health Agency awarded a $1,621,712 Project Grant to The General Hospital Corporation's Research Management Division, operating as Massachusetts General Hospital (MGH), for the "THERAPEUTIC TARGETING OF CHEMORESISTANT RHABDOMYOSARCOMA" project. This award is funded through the Military Medical Research and Development program (CFDA 12.420), which supports a range of biomedical research initiatives to improve health outcomes for military service members, veterans, and the broader public.
The grant will enable MGH to conduct innovative scientific research and clinical studies focused on developing new treatments for chemoresistant rhabdomyosarcoma, an aggressive form of childhood cancer. As a prominent academic medical center, MGH has significant expertise in conducting foundational biomedical research, including advanced clinical trials, to advance disease understanding and validate new therapeutic approaches. This federal grant award will allow MGH to leverage its specialized facilities and collaborate with other institutions as part of this multi-year research project.
Generated 3/4/25, 8:09 AM